Since graduating from UL with BSc. Industrial Biochemistry (1997) and PhD (2002), Maureen began her career as a Research Associate at the Wellcome Trust Sanger Institute, Cambridge UK  in the "Atlas of Gene Expression" team. This included building antibody phage libraries from patient material to enable generation of antibodies that would enable mapping of the proteome using immunohistochemistry methodologies. In 2004, she joined a small growing team at Genzyme, Cambridge UK, as part of a new flagship laboratory for antibody discovery to support biologics research for the wider Genzyme company. The team had a focus in both target and antibody discovery using phage display, supporting Oncology and Immunology indications. With the Sanofi acquisition of Genzyme and closure of the site, Maureen relocated to Massachusetts US in 2012 to continue working in the biologics field but within a larger multi-national team within Sanofi. During this time, she led teams for the discovery and optimization of multiple complex mono- and multi-specific biologics. In 2020, Maureen joined Takeda to lead a Biotherapeutic Engineering team whose focus is the use of multiple platforms for both discovery and optimization of biologics of varying formats (mono, multi-specific biologics, cell and gene therapies) to progress within Takeda's pipeline and ultimately to patients.